Scigliano G, Giovannini P, Girotti F, Grassi M P, Caraceni T, Schechter P J
Neurology. 1984 Jan;34(1):94-6. doi: 10.1212/wnl.34.1.94.
In a double-blind, crossover study gamma-vinyl GABA, 2 g/day, and placebo were administered orally for 2 weeks each to six patients with Huntington's disease. Five patients were treated concomitantly with a neuroleptic maintained at constant dose. No consistent beneficial effects on the hyperkinetic movements, abnormal motor function, or ability to carry out normal activities were evident with gamma-vinyl GABA treatment. Treatment was tolerated without clinically significant alterations in the physiologic or biochemical tests used for monitoring. These results suggest that increasing CNS GABAergic function is unlikely to ameliorate Huntington's disease.
在一项双盲交叉研究中，对6例亨廷顿舞蹈病患者，分别给予γ-乙烯基-GABA（2克/天）和安慰剂口服，各治疗2周。5例患者同时接受维持恒定剂量的抗精神病药物治疗。γ-乙烯基-GABA治疗对运动亢进、异常运动功能或进行正常活动的能力均未显示出持续的有益效果。治疗耐受性良好，用于监测的生理或生化检查未出现具有临床意义的改变。这些结果表明，增强中枢神经系统γ-氨基丁酸能功能不太可能改善亨廷顿舞蹈病。
